axovant
gene
therapies
receives
rare
pediatric
disease
designation
gangliosidosis
new
york
globe
newswire
axovant
gene
therapies
nasdaq
axgt
company
developing
innovative
gene
therapies
neurological
diseases
today
announced
received
rare
pediatric
disease
designation
food
drug
administration
fda
gene
therapy
delivered
via
single
intravenous
administration
phase
development
gangliosidosis
addition
rare
pediatric
disease
designation
orphan
drug
designation
gene
therapy
clinical
development
infantile
type
juvenile
type
ii
gangliosidosis
receiving
rare
pediatric
disease
designation
addition
previously
granted
orphan
drug
designation
highlights
importance
expediting
therapy
gangliosidosis
progressive
fatal
pediatric
disease
approved
treatment
options
said
sean
bryan
senior
vice
president
regulatory
affairs
quality
first
gene
therapy
enter
clinical
trials
gangliosidosis
potential
provide
meaningful
clinical
benefit
type
type
ii
axovant
report
stage
data
low
dose
juvenile
cohort
type
ii
fourth
quarter
expects
initiate
high
dose
cohort
includes
infantile
type
juvenile
type
ii
patients
second
half
gangliosidosis
progressive
fatal
pediatric
lysosomal
storage
disorder
caused
mutations
gene
leading
impaired
production
enzyme
currently
approved
treatment
options
gangliosidosis
fda
defines
rare
pediatric
disease
serious
disease
disease
manifestations
primarily
affect
individuals
aged
birth
years
pediatric
diseases
recognized
rare
affect
people
united
states
investigational
gene
therapy
delivers
functional
copy
gene
via
viral
aav
vector
goal
restoring
enzyme
activity
treatment
gangliosidosis
gene
therapy
delivered
intravenously
potential
broadly
transduce
central
nervous
system
treat
peripheral
manifestations
disease
well
preclinical
studies
murine
feline
model
gangliosidosis
supported
ability
improve
enzyme
activity
reduce
ganglioside
accumulation
improve
neuromuscular
function
extend
survival
axovant
licensed
exclusive
worldwide
rights
university
massachusetts
medical
school
development
commercialization
gene
therapy
programs
gangliosidosis
gangliosidosis
including
sandhoff
diseases
axovant
gene
therapies
axovant
gene
therapies
gene
therapy
company
focused
developing
pipeline
innovative
product
candidates
debilitating
neurodegenerative
diseases
current
pipeline
gene
therapy
candidates
targets
gangliosidosis
gangliosidosis
also
known
disease
sandhoff
disease
parkinson
disease
axovant
focused
accelerating
product
candidates
clinical
trials
team
experts
gene
therapy
development
external
partnerships
leading
gene
therapy
organizations
information
visit
statements
press
release
contains
statements
purposes
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
use
words
intended
may
might
would
expect
believe
estimate
similar
expressions
intended
identify
statements
example
statements
axovant
makes
regarding
costs
associated
operating
activities
statements
based
estimates
assumptions
axovant
management
although
axovant
believes
reasonable
inherently
uncertain
statements
subject
risks
uncertainties
may
cause
actual
results
differ
materially
axovant
expected
risks
uncertainties
include
among
others
impact
pandemic
operations
initiation
conduct
preclinical
studies
clinical
trials
availability
data
clinical
trials
scaling
manufacturing
expectations
regulatory
submissions
approvals
continued
development
gene
therapy
product
candidates
platforms
axovant
scientific
approach
general
development
progress
availability
commercial
potential
axovant
product
candidates
statements
also
subject
number
material
risks
uncertainties
described
axovant
recent
quarterly
report
form
filed
securities
exchange
commission
august
updated
subsequent
filings
securities
exchange
commission
statement
speaks
date
made
axovant
undertakes
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
contacts
media
investors
josephine
belluardo
lifesci
communications
jo
media
parag
meswani
axovant
gene
therapies
investors
